GDTC

BEARISH

$1.0 Live

CytoMed Therapeutics Limited · NASDAQ

$0.73 52W Range $3.68

GDTC CytoMed Therapeutics Limited - Fundamental Analysis

BEARISH

Console Chart News

GDTC Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$1.0

52W High

$3.68

52W Low

$0.73

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 10, 2026

Market cap

$11.83M

P/E

N/A

ROE

-50.3%

Profit margin

N/A

Debt/Equity

0.07

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Key Strengths

Strong liquidity position with a Current Ratio of 5.17

Very low leverage (Debt/Equity of 0.07)

High Gross Margin (89.57%) typical of high-potential biotech

Positive year-over-year revenue growth of 46.90%

Quick Ratio of 3.14 indicates ability to cover short-term obligations

Key Risks

Extreme operational inefficiency with an operating margin of -535.25%

Severe multi-year price erosion (-75% over 3-5 years)

Micro-cap volatility and lack of institutional analyst coverage

Negative Return on Equity (-50.28%) and Return on Assets (-29.31%)

High Price/Sales ratio (13.74) relative to sector growth benchmarks

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Severe operating losses, Strong bearish technical trend, Micro-cap liquidity risks, Lack of profitability

Confidence

90%

Value

20/100

P/E N/A; Price/Book 2.31

Positives

Low Debt/Equity

Watchpoints

P/S ratio of 13.74 is excessive for current growth
No Graham Number due to lack of earnings

Future

40/100

Ref Growth rates

Positives

Revenue growth of 46.90%

Watchpoints

Revenue growth lags sector average (105.57%)
Forward P/E remains negative

Past

10/100

Ref Historical trends

Positives

No standout positives identified.

Watchpoints

1Y Change: -63.5%
5Y Change: -75.0%

Health

50/100

Ref Piotroski F-Score

Positives

High Current Ratio
Low Debt

Watchpoints

Piotroski F-Score 4/9 (Marginal)
Negative ROE/ROA

Dividend

0/100

Ref Yield 0%

Positives

No standout positives identified.

Watchpoints

No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$1.0

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for GDTC and closest competitors.

Updated 2026-04-09

Company	5Y	3Y	1Y	6M	1M	1W
GDTC CytoMed Therapeutics Limited Primary	-75.0%	-75.0%	-63.5%	-55.6%	-5.7%	+1.2%
BNGO Bionano Genomics, Inc. Peer	-100.0%	-99.8%	-64.6%	-35.8%	+0.9%	+3.6%
CUPR Cuprina Holdings (Cayman) Limited Peer	-85.5%	-85.5%	-85.5%	-45.3%	+62.6%	+105.3%
BFRI Biofrontera Inc. Peer	-99.0%	-93.2%	-14.4%	-1.0%	+3.1%	-1.7%
BMGL Basel Medical Group Ltd Peer	-82.0%	-82.0%	-82.0%	-64.4%	+23.8%	-3.5%

GDT

CytoMed Therapeutics Limited

Primary

-75.0%

-63.5%

-55.6%

-5.7%

+1.2%

BNG

Bionano Genomics, Inc.

Peer

-100.0%

-99.8%

-64.6%

-35.8%

+0.9%

+3.6%

CUP

Cuprina Holdings (Cayman) Limited

Peer

-85.5%

-45.3%

+62.6%

+105.3%

BFR

Biofrontera Inc.

Peer

-99.0%

-93.2%

-14.4%

-1.0%

+3.1%

-1.7%

BMG

Basel Medical Group Ltd

Peer

-82.0%

-64.4%

+23.8%

-3.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-6.67

N/A

2.31

13.74

12.23

-2.73

$11.83M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -535.25%

Gross Margin 89.57%

ROE -50.28%

ROA -29.31%

Growth

Revenue and earnings growth rates

Revenue Growth +46.9%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.07

Low debt

Current Ratio

5.17

Strong

Quick Ratio

3.14

Excellent

Cash/Share

$0.18

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Total Assets

$0.0B

Liabilities

$0.0B

Equity

$0.0B

Debt/Equity

0.17x

Healthcare Sector Comparison

Comparing GDTC against 205 companies in the Healthcare sector (17 bullish, 70 neutral, 118 bearish)

Return on Equity (ROE)

-50.28%

This Stock

-42.45%

Sector Avg

+18.4% (Excellent)

Debt to Equity

0.07

This Stock

4.76

Sector Avg

-98.5% (Less Debt)

Revenue Growth

46.9%

This Stock

106.86%

Sector Avg

-56.1% (Slower)

Current Ratio

5.17

This Stock

3.53

Sector Avg

+46.1% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
GDTC CytoMed Therapeutics Limited	BEARISH	$11.83M	-	-50.3%	-%	$1.0
BNGO Bionano Genomics, Inc.	BEARISH	$11.7M	-	-78.2%	-134.4%	$1.15	Compare
CUPR Cuprina Holdings (Cayman) Limited	BEARISH	$12.9M	-	-139.1%	-%	$0.6	Compare
BFRI Biofrontera Inc.	BEARISH	$9.97M	-	-1191.7%	-47.3%	$0.86	Compare
BMGL Basel Medical Group Ltd	BEARISH	$15.03M	-	-194.6%	-99.8%	$0.8	Compare

GDTC CytoMed...

BEARISH

Mkt Cap

$12M

P/E

ROE

-50.3%

Price

$1.0

BNGO Bionano Genomics, Inc.

Compare with GDTC

Compare with GDTC

BFRI Biofrontera Inc.

Compare with GDTC

BMGL Basel Medical Group Ltd

Compare with GDTC

Past News Coverage

Recent headlines mentioning GDTC from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

GDTC

GDTC CytoMed Therapeutics Limited - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Healthcare Sector Comparison

Similar Companies

Past News Coverage

Wait — Don't Miss Out!